Szawarnoga Daniel, Fojcik Joanna, Górski Michał, Pałasz Artur, Krzystanek Marek
Department of Psychiatry, Department of Neurology, Faculty of Health Sciences in Katowice, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.
Department of Chronic Diseases and Civilization-Related Hazards, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.
Pharmaceuticals (Basel). 2025 Jul 19;18(7):1066. doi: 10.3390/ph18071066.
Insomnia, as one of the most common sleep disorders, is a significant health problem, especially among patients suffering from drug-resistant depression. Problems related to the quality of sleep in that population can significantly affect the effectiveness of treatment and quality of life, which is why it is necessary to search for effective therapeutic interventions in this area. Objective: The aim of this study was to compare the effectiveness of esketamine and other standard antidepressants in improving sleep quality in patients with drug-resistant depression. The main research question is whether and to what extent esketamine improves sleep parameters compared with other antidepressants. : This study involves the analysis of data collected from 50 patients divided into two groups: those using esketamine in combination with other antidepressants and those using other antidepressants. The analysis of the results focuses on the assessment of differences in AIS scores between the groups assessed using the Athens Insomnia Scale (AIS). Insomnia occurs much less frequently among people using esketamine than among people not using this drug. With the increase in the time of using esketamine and with the increase in the dose, the level of insomnia decreases. Esketamine brings about a rapid improvement in sleep quality, which is a significant advance in the treatment of drug-resistant depression. The obtained results not only confirm the effectiveness of esketamine but also show its advantage over traditional treatment methods in improving sleep quality.
失眠作为最常见的睡眠障碍之一，是一个重大的健康问题，尤其是在患有难治性抑郁症的患者中。该人群中与睡眠质量相关的问题会显著影响治疗效果和生活质量，这就是为什么有必要在这一领域寻找有效的治疗干预措施。目的：本研究旨在比较艾氯胺酮与其他标准抗抑郁药在改善难治性抑郁症患者睡眠质量方面的有效性。主要研究问题是与其他抗抑郁药相比，艾氯胺酮是否以及在多大程度上能改善睡眠参数。：本研究涉及对从50名患者收集的数据进行分析，这些患者分为两组：一组使用艾氯胺酮联合其他抗抑郁药，另一组使用其他抗抑郁药。结果分析重点在于使用雅典失眠量表（AIS）评估的两组之间AIS评分差异。使用艾氯胺酮的人群中失眠的发生率远低于未使用该药物的人群。随着艾氯胺酮使用时间的增加和剂量的增加，失眠水平降低。艾氯胺酮能迅速改善睡眠质量，这是难治性抑郁症治疗方面的一项重大进展。所获得的结果不仅证实了艾氯胺酮的有效性，还表明其在改善睡眠质量方面优于传统治疗方法。
